• Profile

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis

Gut Feb 10, 2022

In this meta-analysis of individual patient data, impacts of direct-acting antiviral (DAA) exposure on hepatocellular carcinoma (HCC) recurrence risk are inconclusive. Active clinical as well as radiological follow-up of patients with HCC after HCV eradication with DAA is valid.

  • From 21 studies of HCV-related cirrhosis and HCC, data were pooled from 977 consecutive patients who achieved complete radiological response following surgical/locoregional treatments and took DAAs (DAA group); propensity score-matched patients from the ITA.LI.CA. cohort (n=328) were DAA-unexposed controls (no-DAA group).

  • In DAA-treated patients, recurrence rate and death risk per 100 person-years were reported to be 20 (95% CI 13.9 to 29.8) and 5.7 (2.5 to 15.3), respectively.

  • Alpha-fetoprotein logarithm, HCC recurrence history pre-DAA initiation, performance status and tumor burden pre-HCC treatment were identified to be predictive factors for recurrence.

  • Relative risk did not differ significantly between the DAA-exposed and DAA-unexposed groups in propensity score-matched patients (relative risk=0.64, 95% CI 0.37 to 1.1).

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen